ARK Investment Management Reduces $11M in Beam Therapeutics Inc. ($BEAM)
Key Points
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
ARK Investment Management trimmed its position in Beam Therapeutics Inc. ($BEAM) by 2.68% during the most recent quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 12,133,433 shares of Beam Therapeutics Inc. after selling 333,756 shares during the quarter. ARK Investment Management's holdings in Beam Therapeutics Inc. were worth $416.42 million as of its most recent filing.
Beam Therapeutics Inc. Stock Up 17.1%
Shares of Beam Therapeutics Inc. ($BEAM) traded around $34.32 on Saturday, up 17.1% for the day.
Beam Therapeutics Inc. Earnings
Analysts Set New Price Targets
About Beam Therapeutics Inc.
Beam Therapeutics Inc., a biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States. Its programs in hematology and genetic disease portfolio include Ristoglogene autogetemcel, a patient-specific, autologous hematopoietic stem cell (HSC) therapy for the treatment of sickle cell disease; BEAM-302, a liver-targeting lipid nanoparticle (LNP) for the treatment of severe alpha-1 antitrypsin deficiency; BEAM-304, a liver-targeting LNP for the treatment of phenylketonuria; and BEAM-301, a liver-targeting LNP formulation for the treatment of glycogen storage disease type 1a. The company also develops the ESCAPE platform, which combines antibody-based conditioning with multiplex gene edited HSCs. In addition, it develops BEAM-103, an anti-CD117 monoclonal antibody that enables ESCAPE. The company has research collaboration agreement with Pfizer Inc., focusing on in vivo base editing programs for targets rare genetic diseases of the liver, muscle, and central nervous system; Verve Therapeutics, Inc., for cardiovascular disease treatments; and Orbital Therapeutics to design RNA for the prevention, treatment, or diagnosis of human disease. Beam Therapeutics Inc. was incorporated in 2017 and is based in Cambridge, Massachusetts.
Get Beam Therapeutics Inc. alerts
New 13F filings, insider trades, and analyst moves on $BEAM, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.